MyHealthChecked PLC
("MyHealthChecked" or the "Company")
At-home wellness tests to launch on Amazon
MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company, announces that its suite of cheek- swab DNA at-home wellness tests will be available from today to purchase through the UK site of online retailer, Amazon.com, Inc. (NASDAQ: AMZN) ("Amazon").
The tests were initially launched by MyHealthChecked and available for purchase on the Company's website on 14 June 2022. Customers will now be able to purchase four tests directly via Amazon UK, with the launch of the Glucose Management DNA test expected to follow. The tests will be priced at £54 per test, and will be delivered to users by Royal Mail Tracked 24.
The tests that will be available in MyHealthChecked's at-home wellness range and launching on Amazon are:
| Intolerances & Sensitivities | to identify genetic variants associated with intolerances, such as gluten and lactose, as well as sensitivities, including caffeine, salt and alcohol |
| Weight Management | intended for use by those wishing to identify their genetic susceptibility to becoming overweight and their responsiveness to weight loss interventions at a molecular and metabolic level, including genetic interactions |
| Heart Profile | identifying how individuals respond differently to diet. This will facilitate optimisation of heart health parameters by using personalised dietary advice |
| Vitamins & Minerals | this test indicates the predisposition towards a nutrient deficiency or toxicity, to highlight nutrients or supplements an individual should increase or deprioritise |
MyHealthChecked's range of at-home wellness tests allow individuals to make more informed choices about their health and well-being from personalised, accurate results and advice. Understanding genetic disposition provides individuals with the power to be proactive about their health and well-being through lifestyle and diet management, allowing individuals to fully unlock their health potential.
The launch of the tests via Amazon supports the Company's strategy of accessible healthcare for all, enabling the Company to broaden its reach, as the demand for health and wellness tests expands. All tests will continue to be available via the MyHealthChecked website (www.myhealthchecked.com/wellness), also priced at £54 per test, which also provides access to information about the benefits of DNA use, details of the Scientific Advisory team and full customer facts and questions.
Penny McCormick, Chief Executive Officer of MyHealthChecked Plc, said: "We are excited to be launching our wellness tests with Amazon and believe this will greatly increase the accessibility of our product range. Following the success of our partnership with the UK's top high street pharmacy retailers for our COVID testing service, we have seen the real value that additional retail partners can bring to the business by broadening our customer base and significantly increasing our market share."
For further information contact:
| MyHealthChecked plc | ||
| Penny McCormick, Chief Executive Officer | via Walbrook PR | |
| | | |
| SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 | |
| Neil Baldwin | | |
| | | |
| Oberon Capital Ltd (Broker) | Tel: +44 (0)20 3179 5344 | |
| Mike Seabrook | ||
| | | |
| Walbrook PR Ltd (Media & IR) | Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com | |
| Paul McManus / Alice Woodings | Mob: +44(0)7980 541 893 / +44(0) 7407 804 654 | |
About MyHealthChecked PLC (www.myhealthcheckedplc.com)
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.
MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests that have been developed following the acquisition of The Genome Store in November 2020. The tests are available online, and in some cases, for over-the-counter purchase.
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.